EUVIMEDEUVIMED entdecken
Open Access

In situ–formed immunotherapeutic hydrogel containing sphingosine-1-phosphate for enhanced lung cancer immunotherapy

Hui Shen iD, Qi Deng iD, Zhike Chen iD, Qiang Zhang iD, Xiao Zhou iD, Qian Chen iD, Jiang Fan iD

Science Advances · 2025

DOI: 10.1126/sciadv.adw5001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Hui Shen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200086, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Hydrogels, Sphingosine, Lysophospholipids. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Limited infiltration of immune cells within tumors restricts the therapeutic efficiency of immune checkpoint blockades. Herein, we discover that sphingosine-1-phosphate (S1P) is down-regulated in patients with lung cancer who do not respond to PD-1/PD-L1 therapy. Our findings indicate that S1P gradient enhances the migration and viability of immune cells and promotes the polarization of macrophages toward the M1 phenotype primarily through mitochondrial reactive oxygen species–activated nuclear factor κB and Janus kinase–signal transducers and activators of transcription signaling pathways. To capitalize on these findings, we used a biodegradable sodium alginate hydrogel as a delivery system for the sustained and sequential release of S1P and anti–PD-L1 (αPDL1). In vivo studies demonstrated that S1P-αPDL1@Gel effectively inhibited tumor growth and reduced the recurrence of local tumors after surgery. Additionally, the hydrogel significantly enhanced the infiltration of dendritic cells, M1 macrophages, CD4 + T cells, and CD8 + T cells. S1P-αPDL1@Gel holds a promising therapeutic strategy for remodeling the immunosuppressive tumor microenvironment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsHydrogelsSphingosineLysophospholipidsImmunotherapyHumansAnimalsMiceTumor MicroenvironmentB7-H1 AntigenCell Line, TumorMacrophagesFemale

Substanzen

Hydrogelssphingosine 1-phosphateSphingosineLysophospholipidsB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200086, China.
  • Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, China.
  • Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  • Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
  • School of Materials Science and Engineering, Tongji University, Shanghai 201804, China.

ORCID-Profile: Hui Shen, Qi Deng, Zhike Chen, Qiang Zhang, Xiao Zhou, Qian Chen, Jiang Fan

Zitieren

APA

Shen, H., Deng, Q., Chen, Z., Zhang, Q., Zhou, X., Chen, Q., & Fan, J. (2025). In situ–formed immunotherapeutic hydrogel containing sphingosine-1-phosphate for enhanced lung cancer immunotherapy. Science Advances. https://doi.org/10.1126/sciadv.adw5001

Vancouver

Shen H, Deng Q, Chen Z, Zhang Q, Zhou X, Chen Q, et al. In situ–formed immunotherapeutic hydrogel containing sphingosine-1-phosphate for enhanced lung cancer immunotherapy. Science Advances. 2025. doi:10.1126/sciadv.adw5001

BibTeX
@article{Shen2025,
  author = {Shen, Hui and Deng, Qi and Chen, Zhike and Zhang, Qiang and Zhou, Xiao and Chen, Qian and Fan, Jiang},
  title = {In situ–formed immunotherapeutic hydrogel containing sphingosine-1-phosphate for enhanced lung cancer immunotherapy},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adw5001}
}
Kostenlos starten →